Wyeth Duract Withdrawn After Continued Reactions To Long-Term Use
Executive Summary
Further efforts to limit Wyeth-Ayerst's Duract to short-term use "would not be practical or effective," FDA said in explaining the company's June 22 market withdrawal of the non-steroidal anti-inflammatory drug bromfenac.
You may also be interested in...
Purdue OxyContin False Advertising Suit Dismissed; No Economic Harm Shown
A lawsuit alleging fraudulent advertising of Purdue's OxyContin does not establish grounds for economic injury, a federal court ruled
Purdue OxyContin False Advertising Suit Dismissed; No Economic Harm Shown
A lawsuit alleging fraudulent advertising of Purdue's OxyContin does not establish grounds for economic injury, a federal court ruled
Analgesic Acute Pain Trials Should Assess Long-Term, Multi-Dose Safety
Analgesic acute pain trails should assess long-term safety and multiple doses, members of FDA's Arthritis Advisory Committee suggested July 30